Huong Nguyen, MD
Family Medicine · San Diego, CANPI 1265506794
Payments from drug & device makers
Across 176 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$656
- Amgen$392
- Abbott$363
- Vanda Pharmaceuticals Inc.$243
- Kowa Pharmaceuticals America, Inc.$116
- plus $931 from 21 others
What the payments were for
- Food & beverage$4,08399%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 61 | $1,407 |
| GSK | 26 | $656 |
| Amgen | 18 | $392 |
| Abbott | 10 | $363 |
| Vanda Pharmaceuticals Inc. | 8 | $243 |
| Kowa Pharmaceuticals America, Inc. | 5 | $116 |
| Pfizer | 5 | $115 |
| Radius Health, Inc. | 4 | $94 |
| Cranial Technologies, Inc | 6 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $89 |
| Novo Nordisk | 5 | $88 |
| Redhill Biopharma Inc. | 3 | $59 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| AbbVie | 2 | $38 |
| Phadia US Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Exact Sciences | 2 | $36 |
| Bayer | 2 | $32 |
| Shield Therapeutics Inc | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Insulet Corporation | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Nevro Corp. | 1 | $19 |
| Metacel Pharmaceuticals LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,108 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 96 | $71,979 |
| TradjentaLinagliptin | 69 | $61,545 |
| OzempicSemaglutide | 48 | $60,011 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 85 | $53,338 |
| JanuviaSitagliptin Phosphate | 65 | $48,340 |
| ProliaDenosumab | 30 | $48,261 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 52 | $26,282 |
| EliquisApixaban | 24 | $23,869 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $17,278 |
| TrulicityDulaglutide | 12 | $13,050 |
| Fluticasone Propionate HfaFluticasone Propionate | 50 | $10,720 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $9,762 |
| Celecoxib | 442 | $9,176 |
| LinzessLinaclotide | 14 | $8,651 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $8,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,407 | $125,317181 claims |
| Boehringer IngelheimTradjenta | $17 | $61,54569 claims |
| Novo NordiskOzempic | $88 | $60,01148 claims |
| AmgenProlia | $392 | $48,26130 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $656 | $27,04052 claims |
| PfizerEliquis | $115 | $23,86924 claims |
| Lilly USA, LLCTrulicity | $36 | $13,05012 claims |
| AbbVieLinzess | $38 | $8,65114 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $15 | $3,40417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in San Diego
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Laurie Han-ConradSan Diego$2.9M
- Sheldon MorrisSan Diego$1.1M
- Mirwais SaifiSan Diego$1M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.